Price Action To Observe: SAGE Therapeutics Inc Just Recorded A Sigfniciant Increase

Price Action To Observe: SAGE Therapeutics Inc Just Recorded A Sigfniciant Increase

The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) is a huge mover today! The stock increased 3.62% or $1.78 on November 23, hitting $50.99. About 450,188 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 30.14% since April 22, 2016 and is uptrending. It has outperformed by 24.73% the S&P500.
The move comes after 9 months positive chart setup for the $1.83 billion company. It was reported on Nov, 24 by Barchart.com. We have $52.52 PT which if reached, will make NASDAQ:SAGE worth $54.90 million more.

Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on February, 22. They expect $-1.14 EPS, down 15.15% or $0.15 from last year’s $-0.99 per share. After $-1.15 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts -0.87% EPS growth.

SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage

Out of 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 8 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 80% are positive. $90 is the highest target while $18 is the lowest. The $68.75 average target is 34.83% above today’s ($50.99) stock price. SAGE Therapeutics has been the topic of 11 analyst reports since September 3, 2015 according to StockzIntelligence Inc. Stifel Nicolaus initiated the stock with “Buy” rating in Monday, November 14 report. The firm has “Sell” rating by Chardan Capital Markets given on Tuesday, May 24. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has “Buy” rating given on Friday, March 11 by Lake Street. The firm earned “Outperform” rating on Wednesday, June 29 by BMO Capital Markets. JP Morgan maintained the shares of SAGE in a report on Thursday, September 3 with “Buy” rating. As per Thursday, June 23, the company rating was initiated by H.C. Wainwright. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, March 30. The company was maintained on Thursday, September 3 by Leerink Swann. On Tuesday, September 13 the stock rating was initiated by Raymond James with “Outperform”.

According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 1.47 in Q2 2016. Its down 0.04, from 1.51 in 2016Q1. The ratio turned negative, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
Spark Llc reported 12,000 shares or 0.03% of all its holdings. Brown Brothers Harriman And Company last reported 92 shares in the company. Hamilton Lane Advsrs Ltd Liability Corporation, a Pennsylvania-based fund reported 10,000 shares. Sabby Mgmt last reported 68,950 shares in the company. Ubs Oconnor Ltd Company has 0% invested in the company for 18,960 shares. Rockefeller Serv last reported 0% of its portfolio in the stock. Ser Automobile Association last reported 0% of its portfolio in the stock. The California-based Rs Inv Lc has invested 0.18% in SAGE Therapeutics Inc (NASDAQ:SAGE). Cap Impact Advsrs Llc last reported 0.11% of its portfolio in the stock. D E Shaw accumulated 0% or 16,978 shares. California State Teachers Retirement Systems has 55,542 shares for 0% of their US portfolio. Palisade Management Ltd Limited Liability Company Nj has 25,519 shares for 0.03% of their US portfolio. Marshall Wace Llp reported 690,965 shares or 0.18% of all its holdings. State Board Of Administration Of Florida Retirement System accumulated 0% or 10,316 shares. The Ontario – Canada-based Comml Bank Of Montreal Can has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE).

Insider Transactions: Since July 12, 2016, the stock had 0 buys, and 5 sales for $1.51 million net activity. IGUCHI KIMI also sold $102,325 worth of SAGE Therapeutics Inc (NASDAQ:SAGE) shares. 22,000 SAGE Therapeutics Inc (NASDAQ:SAGE) shares with value of $880,000 were sold by Robichaud Albert.

More important recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Prnewswire.com published article titled: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016”, Valuewalk.com published: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” on April 01, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) was released by: Fool.com and their article: “Here’s Why Sage Therapeutics’ Stock Is Falling Today” with publication date: March 23, 2016.

SAGE Company Profile

SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment